Plain-English translation of NCT06497387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called , which uses your own immune cells that are engineered in a laboratory to target and fight disease-causing cells. The medication is being studied in people with severe lupus kidney disease or IgG4-related disease that hasn't responded well to standard treatments. Researchers want to find the safest and most effective dose of this treatment.
Lupus kidney disease and IgG4-related disease can cause serious kidney damage, and some people don't improve with conventional medications. This study exists to see if this new cell-based treatment can help people whose disease hasn't responded to standard care.
You likely qualify if…
You likely don't qualify if…
The study happens in two phases. First, researchers test different doses of the medication in small groups to find the safest level. Once a safe dose is identified, more participants receive that dose to confirm it works well for lupus kidney disease and IgG4-related disease separately. You will have your blood cells collected, sent to a lab where they are engineered, and then infused back into your body. You'll have multiple clinic visits for blood tests, scans, and health monitoring to watch for side effects and see if the treatment is helping.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China